Gene Therapy Phase 3 Licensing Benchmarks
Deal economics across 14 transactions with 12 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$430M
12 deals with terms
Median Total Value
$2.0B
Upfront + milestones
Royalty Range
11.9%--24.6%
Average low--high
Deal Count
14
2019--2026
The median upfront payment for phase 3 gene therapy licensing deals is $430M, based on 12 deals with disclosed terms from 2019--2026. Total deal values (including milestones) reach a median of $2.0B. Royalty rates typically range from 11.9% to 24.6%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| AveXis | Novartis | 2019 | $8.7B | $8.7B |
| CG Oncology | Johnson & Johnson | 2024 | $1.7B | $3.0B |
| Arcus Biosciences | GSK | 2024 | $939M | $7.8B |
Showing 3 of 12 deals with disclosed terms. Full comp set available in the report.
Full gene-therapy phase-3 Comp Set
Get the complete analysis -- 12 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific gene therapy asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2019--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.